menu
    • menu
    [{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Paul Scherrer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Terbium-161","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Paul Scherrer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Isotope Technologies Munich \/ Paul Scherrer Institute"},{"orgOrder":0,"company":"TerThera","sponsor":"Radiopharm Theranostics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"RAD 402","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TerThera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TerThera \/ Radiopharm Theranostics","highestDevelopmentStatusID":"4","companyTruncated":"TerThera \/ Radiopharm Theranostics"}]

    Find Clinical Drug Pipeline Developments & Deals for Terbium-161

    Menu

    Terbium-161

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TerThera

                            Netherlands arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            TerThera

                            Netherlands arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RAD 402,Terbium-161

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Radiopharm Theranostics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Radiopharm Theranostics Expands Supply Agreement with TerThera for Terbium-161 Isotope Use in Prostate Cancer

                            Details : Under the agreement, TerThera will supply Radiopharm with Terbium-161 and Tb-161 isotope will be linked to a proprietary mAb to form RAD 402, a radiotherapeutic that is being developed by Radiopharm to target KLK3 expression in patients with advanced pro...

                            Brand Name : RAD 402

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 24, 2023

                            Lead Product(s) : RAD 402,Terbium-161

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Radiopharm Theranostics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Isotope Technologies Munich

                            Germany arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Isotope Technologies Munich

                            Germany arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Terbium-161

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Paul Scherrer Institute

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufactur...

                            Details : Under the agreement, the partners will combine their respective technologies and expertise in the production of terbium-161 including clinical and commercial use in Targeted Radionuclide Therapy (TRT) for the treatment of cancer.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 27, 2023

                            Lead Product(s) : Terbium-161

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Paul Scherrer Institute

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth